According to Zacks, “Agenus has several collaboration agreements, which not only validate its technology platforms but also provide funds. The company received a boost when Merck selected its lead antibody candidate and several backup antibodies to an undisclosed checkpoint target. Agenus is developing its anti-CTLA-4 antibody, AGEN1884, and its anti-GITR checkpoint antibody, INCAGN1876, in partnership with Incyte. We are encouraged by the company’s efforts in developing Prophage vaccine for glioblastoma multiforme. However, Agenus is heavily dependent on its partners for pipeline development. Agenus has only a few candidates in mid-stage of development including Prophage vaccine and a number of QS-21 Stimulon-containing vaccine candidates. Any unfavorable outcome from the studies may affect shares adversely.”
A number of other brokerages have also recently commented on AGEN. Jefferies Group reaffirmed a buy rating on shares of Agenus in a report on Tuesday, August 23rd. HC Wainwright reaffirmed a buy rating and issued a $10.00 target price on shares of Agenus in a report on Sunday, July 31st. Finally, Maxim Group reissued a buy rating and set a $7.00 price target on shares of Agenus in a report on Thursday, July 28th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Agenus currently has a consensus rating of Buy and a consensus target price of $10.25.
Agenus (NASDAQ:AGEN) traded down 1.27% on Wednesday, reaching $7.02. 137,899 shares of the company’s stock were exchanged. The company’s market cap is $610.12 million. The firm has a 50 day moving average of $6.39 and a 200-day moving average of $4.78. Agenus has a 12-month low of $2.61 and a 12-month high of $7.31.
Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, July 28th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. Agenus had a negative net margin of 328.53% and a negative return on equity of 138.27%. The business earned $6.59 million during the quarter, compared to analysts’ expectations of $5.12 million. Equities analysts expect that Agenus will post ($1.27) EPS for the current fiscal year.
In related news, Director Ulf Wiinberg bought 30,000 shares of the stock in a transaction on Tuesday, September 6th. The shares were bought at an average cost of $6.29 per share, for a total transaction of $188,700.00. Following the completion of the transaction, the director now owns 30,000 shares of the company’s stock, valued at approximately $188,700. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of AGEN. BlackRock Advisors LLC raised its position in shares of Agenus by 2.2% in the second quarter. BlackRock Advisors LLC now owns 34,250 shares of the company’s stock valued at $139,000 after buying an additional 722 shares during the last quarter. Blair William & Co. IL raised its stake in Agenus by 45.9% in the second quarter. Blair William & Co. IL now owns 59,700 shares of the company’s stock valued at $189,000 after buying an additional 18,775 shares in the last quarter. Creative Planning raised its stake in Agenus by 2.8% in the second quarter. Creative Planning now owns 64,171 shares of the company’s stock valued at $260,000 after buying an additional 1,762 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its stake in Agenus by 56.7% in the first quarter. Metropolitan Life Insurance Co. NY now owns 77,931 shares of the company’s stock valued at $324,000 after buying an additional 28,187 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in Agenus by 15.2% in the second quarter. Rhumbline Advisers now owns 94,272 shares of the company’s stock valued at $382,000 after buying an additional 12,417 shares in the last quarter. Institutional investors own 40.63% of the company’s stock.
Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.